Vivos Therapeutics, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On June 30, 2026, Vivos Therapeutics issued Units consisting of Series A Convertible Preferred Stock (convertible 1:1 to Common Stock at Market Price ≈$0.456/share), Common Stock Warrants (5-year term, 100% coverage of conversion shares), and transferable subscription Rights (staged inducement: 2, 1, or 0 Rights per Unit based on funding date through July 31, 2026). Aggregate subscription amount not fully disclosed in exhibits, but structure is classic PIPE with registration rights and tiered dilution. Purchasers are accredited investors; securities restricted pending effectiveness of resale registration statement (S-1 or S-3) within 90 days of closing.
Why this rating
Capital raise size unclear from exhibits; typical structure for micro-cap. 1:1 conversion + full-warrant coverage + Rights = heavy dilution, but company acknowledges this. No material change of control or covenant breach disclosed. Boilerplate PIPE documentation.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.